ImpediMed Limited (ASX:IPD)
Australia flag Australia · Delayed Price · Currency is AUD
0.0340
+0.0010 (3.03%)
Apr 24, 2025, 4:10 PM AEST

ImpediMed Company Description

ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe.

The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment.

It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.

The company was incorporated in 1999 and is headquartered in Carlsbad, California.

ImpediMed Limited
ImpediMed logo
Country Australia
Founded 1999
Industry Medical Devices
Sector Healthcare
Employees 83
CEO Parmjot Bains

Contact Details

Address:
5900 Pasteur Ct.
Carlsbad, 92008
United States
Phone 760 585 2100
Website impedimed.com

Stock Details

Ticker Symbol IPD
Exchange Australian Securities Exchange
Fiscal Year July - June
Reporting Currency AUD
ISIN Number AU000000IPD8
SIC Code 3845

Key Executives

Name Position
Dr. Parmjot Bains M.D. MD, Chief Executive Officer and Director
McGregor Grant BEc, C.A., FCIS, GAICD Chief Financial Officer and Executive Director
Dennis Schlaht Senior Vice President of Research & Development and Technology
Ashley Munoz Director of Human Resources
Dr. Steven Chen M.B.A., M.D. Chief Medical Center
Leanne Ralph AAICD, ACIS, BBus Company Secretary
Dr. Walton A. Taylor Medical Director